SOURCE: Addison-Davis Diagnostics, Inc.

July 14, 2005 05:30 ET

Addison-Davis Diagnostics to Initiate Strategic Launch of "Drug Stop" Product to Corporations Across the Country

WESTLAKE VILLAGE, CA -- (MARKET WIRE) -- July 14, 2005 -- Addison-Davis Diagnostics, Inc. (OTC BB: ADDI) is pleased to announce that they will be initiating their strategy of targeting corporations with its "Drug Stop" product. The "Drug Stop" product has received a FDA 510(K) Clearance as well as a FDA clearance for sale to the Over-The-Counter market.

Various State Governments' "Drug Free Workplace Initiatives" biggest incentive is to offer Workers Compensation Insurance discounts to companies that have mandatory drug testing. The "Drug Stop" product is a self-regulating urine specimen test using the latest on-site drug screening technology. The process used by the "Drug Stop" product is one of the easiest to use on-site drug screening tests.

"Addison-Davis believes that the various government incentives to have a 'Drug-Free' workplace will open the door for us to the $2.2 Billion substance abuse market," stated Edward W. Withrow III, CEO of Addison Davis Diagnostics, Inc.

About Addison-Davis

Addison-Davis Diagnostics, Inc. is responding to industry demands by supplying quick response diagnostic tests that are user friendly, produce fast simple results and are less costly, less problematic and less time consuming. Addison-Davis is currently focused on bringing fast and reliable "Point-of-Care" Diagnostic Testing through the use of its patented technology to Healthcare Professionals, Hospitals, certain branches of the Government and the Workplace Environment for drugs-of-abuse and medical conditions and diseases.

For more information please visit our website or contact Matt Maguire 1-866 THE APPL(E).

Safe Harbor

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

Contact Information